Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
Astellas Pharma and Kyowa Kirin have reached agreements with the US government under its most-favored-nation (MFN) drug pricing policy, becoming the first Japanese drug makers to do so as Washington ratchets up efforts to bring American prices closer to those…
To read the full story
Related Article
REGULATORY
- Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
September 1, 2026
- MHLW Eyes Tax Exemption for OTC-Like Drug Charges
September 1, 2026
- Cabinet Office Seeks 22 Billion Yen for Clinical Trial Subsidies
September 1, 2026
- US MFN Could Steer Clinical Trials Away from Japan: MHLW Bureau Chief
September 1, 2026
- Suspected Drug Promotion Violations Hit Record Low in FY2025: MHLW
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…